ArticleReproductive sciences (Thousand Oaks, Calif.)2026
Effects of Pre- and Post-treatment of Idebenone on the Side Effects of the Chemotherapy Model with Cyclophosphamide in the Rat Ovary.
Article in Reproductive sciences (Thousand Oaks, Calif.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Cyclophosphamide treatment during chemotherapy can harm the ovaries and result in infertility in females. Idebenone, a synthetic antioxidant, has protective properties in various cells and tissues. This study aimed to investigate whether pre- and post-treatments with idebenone could help preserve the function and structure of rat ovaries in the face of the side effects of cyclophosphamide treatment. Female Wistar rats were divided into four groups: vehicle, cyclophosphamide control, idebenone pre-treatment, and idebenone post-treatment. Treatments lasted 14 days, followed by evaluation of superoxide dismutase (SOD) activity, malondialdehyde (MDA) and anti-Mullerian hormone (AMH) levels, ovarian follicle counts, and expression of GDF9, Bcl-2, and Bax proteins. The results of SOD activity, MDA and AMH levels, number of follicles, and expression of proteins GDF9, Bcl-2, and Bax were significantly more favorable in the experimental groups compared to the control group, and pre-treatment with idebenone was more effective than post-treatment. The results indicate that idebenone may mitigate the side effects of cyclophosphamide on the ovary, thereby improving its function and structure by reducing oxidative stress and apoptosis.
Indexed as
Identifiers
42018211What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.